MNV
Market News Video
MNV MNV 10 Stocks Crossing Below Their 200 Day Moving Average
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Atara Biotherapeutics Breaks Below 200-Day Moving Average - Notable for ATRA
Wednesday, March 3, 6:20 PM ET, by Market News Video Staff

In trading on Wednesday, shares of Atara Biotherapeutics Inc (ATRA) crossed below their 200 day ...

Atara BiotherapeuticsBecomes Oversold (ATRA)
Friday, March 26, 11:55 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

VBK's Holdings Imply 13% Gain Potential
Monday, March 29, 8:38 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Top Buys by Top Brass: Chief Commercial Officer Yarema's $500.4K Bet on ATRA
Wednesday, June 16, 10:27 AM ET, by Market News Video Staff

A company's own top management tend to have the best inside view into the business, ...

Analysts Forecast 21% Upside For IBBQ
Thursday, July 1, 8:06 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Top Buys by Top Brass: Chief Commercial Officer Yarema's $500.4K Bet on ATRA

By Market News Video Staff, Wednesday, June 16, 10:27 AM ET
Play Video: One Reason For Insiders to Buy


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Email EnvelopeFree Email Alerts By Stock:
Get Dividend Alerts
Get SEC Filing Alerts

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $500.4K by Kristin Yarema, Chief Commercial Officer at Atara Biotherapeutics Inc (NASDAQ:ATRA).

Yarema bets big on ATRA:

Purchased Insider Title Shares Price/Share Value
06/14/2021 Kristin Yarema Chief Commercial Officer 34,354 $14.57 $500,369.64

Yarema's average cost works out to $14.57/share. Shares of Atara Biotherapeutics Inc were changing hands at $14.92 at last check, trading up about 6.2% on Wednesday. The chart below shows the one year performance of ATRA shares, versus its 200 day moving average:

Atara Biotherapeutics Inc Chart

Looking at the chart above, ATRA's low point in its 52 week range is $10.38 per share, with $28.20 as the 52 week high point — that compares with a last trade of $14.92.


Special Offer: Join the income investing conversation on ValueForum.com with a special Seven Days for Seven Dollars invitation.


This Article's Word Cloud:   ATRA   Atara   Bets   Biotherapeutics   Brass   Buys   Chief   Commercial   Days   Dollars   Insider   Insiders   Join   Kristin   Looking   Offer   Officer   Place   Presumably   Price   Purchased   Seven   Share   Shares   Special   Start   Title   Value   ValueForum   Wednesday   Yarema   about   average   buys   chart   company   insider   last   make   maybe   mdash   point   share   stock   take   that   their   they   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Top Buys by Top Brass: Chief Commercial Officer Yarema's $500.4K Bet on ATRA | Market News Video | Copyright © 2008 - 2022, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.